Oramed Pharmaceuticals (NASDAQ:ORMP) Announces Quarterly Earnings Results

Oramed Pharmaceuticals (NASDAQ:ORMP) released its earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02, Zacks reports.

Oramed Pharmaceuticals Price Performance

NASDAQ:ORMP opened at $3.31 on Friday. Oramed Pharmaceuticals has a 1-year low of $1.82 and a 1-year high of $3.76. The company has a 50-day moving average of $3.40 and a 200 day moving average of $2.91. The firm has a market cap of $131.74 million, a PE ratio of 2.22 and a beta of 1.31.

Oramed Pharmaceuticals Announces Dividend

The company also recently disclosed a dividend, which was paid on Monday, January 26th. Investors of record on Friday, January 16th were issued a $0.25 dividend. The ex-dividend date was Friday, January 16th. Oramed Pharmaceuticals’s payout ratio is presently 19.84%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Oramed Pharmaceuticals currently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several large investors have recently modified their holdings of the business. Jane Street Group LLC boosted its stake in shares of Oramed Pharmaceuticals by 35.3% during the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 17,510 shares in the last quarter. Bank of America Corp DE raised its stake in Oramed Pharmaceuticals by 4.4% in the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock worth $395,000 after buying an additional 6,261 shares in the last quarter. HRT Financial LP bought a new position in Oramed Pharmaceuticals in the fourth quarter worth approximately $131,000. Marshall Wace LLP purchased a new stake in Oramed Pharmaceuticals during the fourth quarter worth $738,000. Finally, Squarepoint Ops LLC lifted its holdings in Oramed Pharmaceuticals by 95.1% during the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock worth $166,000 after buying an additional 28,406 shares during the period. Institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.